- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCCN's Policy Summit in April Will Provide Guidance on Clinical Trial Design for Personalized Medicine
The National Comprehensive Cancer Network® (NCCN) will host Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies on April 25, 2014 in Bethesda, Maryland, as part of the NCCN Oncology Policy Program.
On April 25, 2014, the
(
) will host the NCCN Oncology Policy Summit titled,
National Comprehensive Cancer NetworkNCCNDesigning Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies
, at the Bethesda Marriott in Bethesda, Maryland.
With cancer increasingly recognized as being comprised of many subtypes differentiated by specific molecular profiles, identifying the most effective combination therapies is challenging. Defining appropriate patient subsets, selecting agents active against specific targets, predicting effective therapeutic combinations, and appropriately interpreting clinical trial results are significant problems for pharmaceutical companies, clinicians, statisticians, and regulators. These issues will need to be addressed in order to meet the needs of people with cancer.
"Groundbreaking research advancements in oncology and the development of biomarkers and targeted therapies present unique challenges in clinical trial design," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "The NCCN Oncology Policy Summit will shed light on the complexities of statistical 'certainty' in small patient populations, consider reimbursement for biomarker testing for eligibility in clinical trial enrollment, and present debate about whether conventional clinical trial design is practical in this new treatment environment."
Read the press release here:
Source: NCCN
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
